Logo
Banner

PARP1/BRD4-IN-1

PARP1/BRD4-IN-1

Catalog No.: PC0081

Size: 50 mg, 100mg, 250mg.


Description

PARP1/BRD4-IN-1 is a potent and highly selective PARP1/BRD4 inhibitor. PARP1/BRD4-IN-1 inhibits the expression and activity of PARP1 and BRD4, and synergistically inhibits the malignant growth of pancreatic cancer cells.

Molecular Weight 506.56
Formula C29H26N6O3
CAS No. 2758117-74-5
SMILES O=C(C1=CC=CC2=C1NC(CN3C(N(C)C4=CC=C(C5=C(C)ON=C5C)C=C4C3C6=CC=CC=C6)=O)=N2)N
Shipping Room temperature in continental US; may vary elsewhere.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro PARP1/BRD4-IN-1 (compound III-7) (0-2 μM; 3-7 days) has potent inhibition of the growth of cancer cell lines.
PARP1/BRD4-IN-1 (0, 1, 2 μM; 4 days) can significantly inhibit the expression of PARP1 and BRD4 at 2 μM in SW1990 cells.
PARP1/BRD4-IN-1 (1, 2 μM; 4 days) arrests the cell cycle at G0/G1 and G2/M phase in SW1990 cells.
PARP1/BRD4-IN-1 (0, 1, 2 μM; 4 days) has the potent efficacy on the apoptosis of SW1990 cells at 2 μM.
PARP1/BRD4-IN-1 (1, 2 μM; 4 days) regulates the expression of HEXIM1, c-Myc, FOXO1, MDC1 and TOPBP1 to enhance the inhibition of DNA repair in SW1990 cells.
In Vivo PARP1/BRD4-IN-1 (30mg/kg; intraperitoneal injection for 28 days) can significantly inhibit the tumor size and weight, and does not cause significant damage of the kidney, lung, spleen, liver and heart in mice.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.